MARKET

PTCT

PTCT

PTC Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.92
-1.41
-2.64%
After Hours: 52.47 +0.55 +1.07% 16:11 01/24 EST
OPEN
53.56
PREV CLOSE
53.33
HIGH
53.88
LOW
51.81
VOLUME
501.30K
TURNOVER
--
52 WEEK HIGH
54.37
52 WEEK LOW
27.53
MARKET CAP
3.20B
P/E (TTM)
-12.7866
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PTCT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PTCT News

  • Roche's risdiplam successful in SMA study
  • seekingalpha.1d ago
  • UPDATE: Cantor Fitzgerald On PTC Therapeutics Is 'confident in a May approval or earlier based on the data generated between FIREFISH and SUNFISH, and we think that an oral medicine is a game changer in this population taking intrathecal injections'
  • Benzinga.1d ago
  • UPDATE: Cantor Fitzgerald Maintains Overweight On PTC Therapeutics, Raises Target To $81 As Firm Notes 'Risdiplam will be a blockbuster' Adjusts 'PoS for risdiplam to 100% from 75% and factored in the milestones in the coming years'
  • Benzinga.1d ago
  • Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $81
  • Benzinga.1d ago

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About PTCT

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
More

Webull offers PTC Therapeutics, Inc. (PTCT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.